Citation

Choi WW, Lee K, Lee BJ, Park SU, Park JM, Ko CN, Bu Y. Evid. Based Complement. Alternat. Med. 2017; 2017: e7326107.

Affiliation

College of Korean Medicine, Kyung Hee University, Seoul 02447, Republic of Korea.

Copyright

(Copyright © 2017, Hindawi Publishing)

DOI

10.1155/2017/7326107

PMID

28684970

PMCID

PMC5480248

Abstract

Chunghyul-Dan (CHD) is the first choice agent for the prevention and treatment of stroke at the Kyung Hee Medical Hospital. To date, CHD has been reported to have beneficial effects on brain disease in animals and humans, along with antioxidative and anti-inflammatory effects. The aim of this study was to evaluate the pharmacological effects of CHD on a traumatic brain injury (TBI) mouse model to explore the possibility of CHD use in patients with TBI. The TBI mouse model was induced using the controlled cortical impact method. CHD was orally administered twice a day for 5 d after TBI induction; mice were assessed for brain damage, brain edema, blood-brain barrier (BBB) damage, motor deficits, and cognitive impairment. Treatment with CHD reduced brain damage seen on histological examination and improved motor and cognitive functions. However, CHD did not reduce brain edema and BBB damage. In conclusion, CHD could be a candidate agent in the treatment of patients with TBI. Further studies are needed to assess the exact mechanisms of the effects during the acute-subacute phase and pharmacological activity during the chronic-convalescent phase of TBI.

Language: en